Abstract
Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of neurochemicals and has the potential to differentiate between the pathologically distinct diseases, multiple sclerosis (MS) and AQP4Ab-positive neuromyelitis optica spectrum disorder (AQP4Ab-NMOSD). In this study we characterised the metabolite profiles of brain lesions in 11 MS and 4 AQP4Ab-NMOSD patients using an optimised MRS methodology at ultra-high field strength (7T) incorporating correction for T2 water relaxation differences between lesioned and normal tissue.
MS metabolite results were in keeping with the existing literature: total NAA was lower in lesions compared to normal appearing brain white matter (NAWM) with reciprocal findings for Inositol. An unexpected subtlety revealed by our technique was that total NAA differences were driven by NAA-glutamate (NAAG), a ubiquitous CNS molecule with functions quite distinct from NAA though commonly quantified together with NAA in MRS studies as total NAA. Surprisingly, AQP4Ab-NMOSD showed no significant differences for total NAA, NAA, NAAG or Inositol between lesion and NAWM sites, nor were there any differences between MS and AQP4Ab-NMOSD for a priori hypotheses. Post-hoc testing did however reveal greater total NAA in MS compared to AQP4Ab-NMOSD NAWM. Post-hoc testing also revealed a significant correlation between NAWM Ins:NAA and disability (as measured by EDSS) for disease groups combined, driven by the AP4Ab-NMOSD group.
Utilising an optimised MRS methodology, our study highlights some under-explored subtleties in MRS profiles, such as the absence of Inositol concentration differences in AQP4Ab-NMOSD brain lesions versus NAWM and the important influence of NAAG differences between lesions and normal appearing white matter in MS.
Competing Interest Statement
SM reported receiving travel grants from Biogen, Novartis, Bayer, Merck & Co, Roche, and Almirall and honorarium from Biogen for advisory work. GD is supported by the NIHR Biomedical Research Centre (BRC), Oxford and has research funding from the Oxford BRC, MRC(UK), UK MS Society, and National Health and Medical Research(Australia). GD has received travel expenses from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, American Academy of Neurology, and MS Academy, and honoraria as an invited speaker for Novartis, American Academy of Neurology, and MS Academy.
Funding Statement
This work was funded by the MS Society (grant number 858/07) and the Guthy Jackson Charitable Foundation. The research was additionally supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, and the NIHR Oxford Health Biomedical Research Centre. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z). GT holds an Institutional Strategic Support Fund (ISSF) Fellowship funded by the Wellcome trust and received funding from the Economic and Social Research Council's (ESRC's) postdoctoral fellowship programme prior to the current post. CJS holds a Sir Henry Dale Fellowship, funded by the Wellcome Trust and the Royal Society (102584/Z/13/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Oxfordshire REC A 10/H0604/99 Berkshire REC 13/SC/0238
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due the clinically sensitive nature of the data it is have not been made freely available. However, should you or your organisation have an interest in acquiring this data for the purpose of furthering the understanding of multiple sclerosis and neuromyelitis optica, please get in touch with the corresponding author.
Abbreviations
- Asc
- ascorbate
- Cr
- creatine
- GABA
- gamma aminobutyric acid
- Glc+Tau
- glucose and taurine
- Gln
- glutamine
- Glu
- glutamate
- Glx
- Gln + Glu
- GPC
- glycerophosphocholine
- GSH
- glutathione
- Ins / Inositol
- myo-inositol
- NAA
- N-acetylaspartate (i.e. not including NAAG)
- NAAG
- N-acetylaspartylglutamate
- PCr
- phosphocreatine
- PE
- phosphorylethanolamine
- Tau
- taurine
- tCho
- total choline (GPC + Cho)
- tCr
- total creatine (Cr + PCr)
- tNAA
- total N-acetylaspartate (NAA + NAAG)
